You are here:
Company

BiOrion

Back to overview

BiOrion develops products for the diagnostics and treatment of fibrosis, the process of scarring in organs such as the liver, kidneys, heart and lungs that can cause them to fail.

BiOrion belongs to the fund:

Carduso Capital B.V.">

Carduso Capital participates in technology companies that are preferably based on the know-how represented in and originating from the Groningen science cluster in and around the University of Groningen (RUG) and the ...

Pharma Connect Capital">

Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects...

View all the funds from the IFG